High ORR with sequential regimen in CLL

Micrograph showing CLL
A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or relapsed/refractory (RR) chronic lymphocytic leukemia (CLL), results of the CLL2-BAG study suggest. Patients who received bendamustine followed by obinutuzumab and venetoclax achieved an ORR of 95%, and 87% of them were negative... [Read Article]

CHMP recommends new indication for obinutuzumab

Micrograph showing FL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for obinutuzumab (Gazyvaro). The new proposed indication is for obinutuzumab in combination with chemotherapy for patients with previously untreated, advanced follicular lymphoma (FL). This would be followed by obinutuzumab maintenance in patients... [Read Article]

CAR T-cell therapy ‘highly effective’ in high-risk CLL

Cameron Turtle, MBBS, PhD
Photo by Robert Hood,
Fred Hutchinson Cancer
Research Center
A chimeric antigen receptor (CAR) T-cell therapy is “highly effective” in high-risk patients with chronic lymphocytic leukemia (CLL), according to researchers. The CD19 CAR T-cell therapy, JCAR014, produced an overall response rate of 71% and a complete response (CR) rate... [Read Article]

PD-1 inhibitors treat resistant gray zone lymphoma

Doctor evaluating patient
Photo courtesy of the CDC
Three case reports published in The New England Journal of Medicine describe the successful use of PD-1 inhibitors in gray zone lymphoma. Two patients who had failed treatment with DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab) ultimately responded to treatment with pembrolizumab.... [Read Article]

Nivolumab for long-term treatment of cHL after auto-HSCT

Micrograph showing HL
Nivolumab can provide long-term treatment for a broad range of adults who have relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic stem cell transplant (auto-HSCT), according to a presentation at the 14th International Conference on Malignant Lymphoma (ICML). In the phase 2 CheckMate-205 study, cHL patients achieved... [Read Article]

FDA clears use of reagents to detect hematopoietic neoplasia

Blood samples
Photo by Graham Colm
The US Food and Drug Administration (FDA) has allowed marketing of the ClearLLab Reagent Panel, a combination of conjugated antibody cocktails designed to aid the detection of hematopoietic neoplasia. This includes chronic and acute leukemias, non-Hodgkin lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. The ClearLLab reagents are... [Read Article]

Drug granted PRIME access as treatment for DLBCL

Micrograph showing DLBCL
The European Medicines Agency (EMA) has granted polatuzumab vedotin access to the agency’s PRIority MEdicines (PRIME) program. The access is for polatuzumab vedotin when used in combination with rituximab and bendamustine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin is an anti-CD79b antibody drug... [Read Article]